Daniel Payne , 2025-05-12 13:39:00
WASHINGTON — The Trump administration on Monday unveiled a sweeping plan to try to lower prescription drug prices, one that calls for not only basing prices on those paid by other countries but also tighter enforcement of anti-competitive practices. The plan also leaves the door open to an expansion of medications from overseas.
The actions are far more aggressive than those in President Trump’s first term — and are meant to push drugmakers to make a deal with the administration or face consequences from agencies across the federal government.
The Department of Health and Human Services will negotiate direct-to-consumer prices “where appropriate,” aiming for prices comparable to those in other countries, a White House official said in a briefing for reporters speaking on condition of anonymity.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
